- 01/12/2019
- 2019 lenvatinib launching ceremony jointly held by eisai china and msd china
- 01/04/2019
- new drug application for perampanel designated for priority review by china national medical products administration for adjunctive treatment of partial onset seizures
- 11/27/2018
- 25 students from china medical university win eisai china scholarships and grants
- 11/22/2018
- eisai to present latest data on perampanel at 72nd american epilepsy society annual meeting
- 11/12/2018
- eisai launches lenvima® (lenvatinib) in china
- 11/07/2018
- eisai china commences full-scale operation of new suzhou plant
- 10/27/2018
- eisai china inc. held the "2018 ads"
- 10/26/2018
- eisai presents new data on lemborexant for treatment of irregular sleep-wake rhythm disorder in patients with alzheimer’s disease at the 11th clinical trials in alzheimer’s disease conference
- 10/25/2018
- eisai and biogen announce presentation of additional data from the phase ii clinical trial of ban2401 in early alzheimer’s disease at the 2018 clinical trials on alzheimer’s disease (ctad) conference
- 10/23/2018
- eisai china donates approximately rmb2.5 million yuan worth of medicines to the “health to countryside” project for five consecutive years
